HARTFORD–U.S. Senator Chris Murphy (D-Conn.) announced on Monday that Aspira Women’s Health, a bio-analytical company based in Shelton, was named “Innovator of the Month” for its leadership in the development of blood tests that aid in the detection of ovarian cancer. The company’s flagship products, OvaWatch and Ova1Plus, employ AI technology towards effective ovarian cancer risk assessment and drive higher standard of care for women with ovarian masses. Last month, Aspira was awarded $10 million in federal funding to develop a non-invasive blood test to detect endometriosis, which is currently diagnosed through invasive surgery.

“For decades, underinvestment in women’s health has meant that women and girls simply aren’t getting access to the treatments and care they deserve. I’m proud to see Aspira’s cutting-edge biomedical research positioning Connecticut as a leader in women’s healthcare and improving lives through earlier risk assessment, more accurate diagnoses, and innovative, personalized care,” said Murphy.

“We are honored to be Innovator of the Month and proud to represent Connecticut on the national women’s healthcare stage. For far too long, women have been forced to resort to surgical interventions for diagnosis of gynecologic diseases. Aspira aims to change that. We believe all women deserve the opportunity to make healthcare decisions based on facts instead of fear,” said Nicole Sandford, CEO of Aspira Women’s Health. “Endometriosis is a chronic condition that impacts as many as six million women in the United States alone. It alters nearly every facet of a patient’s life, many of whom must wait years for a diagnosis. We believe Aspira is uniquely qualified to solve this problem. Our diagnostic solutions focus on a data-driven approach and powerful AI-enabled algorithms that offer noninvasive alternatives to aid in the detection of gynecologic disease. Our suite of blood tests to assess ovarian cancer risk in women with masses which have been ordered by healthcare providers more than 200,000 times. We believe this experience and experience is critical for the development of a noninvasive endometriosis test.” 

Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.

Murphy believes entrepreneurship and innovation are the building blocks for a strong economy. In the U.S. Senate, he has introduced legislation to incentivize angel investors to put more money into startup companies—the Angel Tax Credit Act and the Helping Angels Lead Our Startups (HALOS) Act. Startup companies create an average of 2 million jobs each year.

###